Chiesi Farmaceutici SpA And SALVAT Sign A Worldwide Development And Licensing Agreement For M3 Muscarinic Receptor Antagonists
1/9/2006 12:30:24 PM
Chiesi Farmaceutici S.p.A. and Laboratorios SALVAT have signed an agreement for the development and licensing of new M3 muscarinic receptor antagonists (anti-M3).
Under the agreement Laboratorios SALVAT grant worldwide exclusive rights to develop, register, manufacture, promote and sell anti-M3 products to Chiesi Farmaceutici. Nonetheless, Salvat keeps rights to co-market products in Spain and in Central America.
comments powered by